Webcast

Meet The CEOs – 21 October

October 21, 2020

Meet The CEOs – 21 October

The Insider (Meet the CEOs) Webcast Replay

This week we were joined by the CEOs of exciting ASX listed businesses, who gave valuable insight to their industries and companies future prospects.

  • (ASX: TD1) TALi Digital Limited – Glenn Smith, Managing Director
  • (ASX: TNT) Tesserent Limited – Julian Challingsworth, Chief Executive Officer
  • (ASX: ATX) Amplia Therapeutics – Dr John Lambert, Chief Executive Officer

Recorded on 21 October 2020 at 12pm (AEDT).

Join the next Meet the CEOs – The Insider webcast

Speak to our Advisor team about this company

FEATURE SPEAKERS

GLENN SMITH

Managing Director - TALi Digital Limited (ASX: TD1)

TALi Digital (ASX: TD1) is an Australian Medical Technology Company seeking to improve attention in early childhood through its breakthrough TALi platform. TALi combines evidence-based proprietary algorithms inside a game-based program to assess and strengthen core attention skills.

JULIAN CHALLINGSWORTH

Chief Executive Officer -Tesserent Limited (ASX: TNT)

Tesserent (ASX: TNT) is Australia’s largest ASX listed cybersecurity provider, is on track to deliver on our strategy to provide clients with a full suite of cybersecurity services: Cyber 360. The company’s Cyber 360 strategy delivers integrated solutions covering identification, protection and 24/7 monitoring against cyber security threats. With in excess of 220 security engineers, Tesserent has the capability to support organisations in defending their digital assets against increasing risks and cyber attacks.

DR JOHN LAMBERT

Chief Executive Officer - Amplia Therapeutics (ASX: ATX)

Amplia Therapeutics (ASX: ATX) is an Australian pharmaceutical company developing new drugs for cancer and fibrosis. The drugs target a protein called Focal Adhesion Kinase (FAK) which is an increasingly important target in cancer biology. Amplia has a particular product development focus in pancreatic and ovarian cancer as well as life-threatening chronic diseases, such as idiopathic pulmonary fibrosis (IPF). The company recently announced the initiation of clinical trials of its lead candidate, AMP945.

Speak to our Advisor team about this company



By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement.